Stock Price
94.34
Daily Change
0.22 0.23%
Monthly
-5.70%
Yearly
51.36%
Q2 Forecast
87.59

Incyte reported $21.28B in Market Capitalization this April of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 4.52B 919M Dec/2025
Agenus USD 107M 16M Dec/2025
Agios Pharmaceuticals USD 1.59B 745M Dec/2025
Alnylam Pharmaceuticals USD 52.54B 7.24B Dec/2025
Amgen USD 176.25B 24.32B Dec/2025
BioCryst Pharmaceuticals USD 1.66B 64M Dec/2025
Biogen USD 25.82B 5.28B Dec/2025
BioMarin Pharmaceutical USD 11.42B 1.02B Dec/2025
Bristol-Myers Squibb USD 109.81B 18.01B Dec/2025
Eli Lilly USD 1.02T 293.84B Dec/2025
Exelixis USD 11.75B 959M Dec/2025
Gilead Sciences USD 152.28B 14.55B Dec/2025
Incyte USD 19.39B 2.83B Dec/2025
Ionis Pharmaceuticals USD 12.81B 2.39B Dec/2025
MacroGenics USD 102M 4M Dec/2025
Merck USD 261.26B 51.62B Dec/2025
Nektar Therapeutics USD 14.34B 13.48B Apr/2026
Neurocrine Biosciences USD 14.14B 218M Dec/2025
Novartis USD 292.21B 26.55B Dec/2025
Novartis USD 263.08B 17.01B Dec/2025
Pfizer USD 141.57B 6.48B Dec/2025
PTC Therapeutics USD 6.1B 1.22B Dec/2025
Regeneron Pharmaceuticals USD 81.12B 21.53B Dec/2025
Sarepta Therapeutics USD 2.26B 238M Dec/2025
Ultragenyx Pharmaceutical USD 2.22B 680M Dec/2025
Vertex Pharmaceuticals USD 115.03B 14.61B Dec/2025